CYP2C19*17 - The Rapid Metabolizer Variant
While most pharmacogenomic attention focuses on loss-of-function variants, the CYP2C19*17 allele11 rs12248560 represents the opposite end of the spectrum: a gain-of-function variant that increases enzyme activity beyond normal levels. This variant sits in the promoter region and upregulates CYP2C19 gene expression.
The Mechanism
The rs12248560 variant22 C>T at position -806 in the promoter region alters a transcription factor binding site in the CYP2C19 promoter. More enzyme means faster metabolism of all CYP2C19 substrates. Homozygous carriers (TT) are classified as ultrarapid metabolizers, while heterozygous carriers (CT) are rapid metabolizers.
Clinical Implications
For proton pump inhibitors (PPIs), rapid and ultrarapid metabolizers break down the
drug too quickly, potentially leading to inadequate acid suppression. Standard PPI
doses may not effectively control acid reflux or heal ulcers. Higher doses or
alternative medications may be needed. The CPIC guideline for PPIs33 CPIC guideline for PPIs
Lima JJ et al. CPIC guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther, 2021
recommends increasing PPI doses by 50-100% for ultrarapid metabolizers.
The Diplotype Complexity
Your overall CYP2C19 status depends on the combination of both alleles. Someone carrying *2/*17 (one loss-of-function, one gain-of-function) presents a classification challenge - current guidelines generally classify this as intermediate metabolizer status, though the clinical impact may vary by medication.
Practical Considerations
If you are a rapid or ultrarapid metabolizer, pay attention to PPI effectiveness. If standard doses of omeprazole or pantoprazole do not adequately control your acid reflux symptoms, your CYP2C19 genotype may be the reason. Discuss with your doctor about dose adjustments or alternative acid-suppressing medications that are not CYP2C19 substrates.